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Quaternary ammonium compounds (QAC) are widely used, cheap, and chemically stable disinfectants and topical antiseptics
with wide-spectrum antimicrobial activities. Within this group of compounds, we recently showed that there are significant dif-
ferences between the pharmacodynamics of n-alkyl quaternary ammonium surfactants (QAS) with a short (C12) alkyl chain
when in vitro toxicities toward bacterial and mammalian epithelial cells are compared. These differences result in an attractive
therapeutic window that justifies studying short-chain QAS as prophylactics for sexually transmitted infections (STI) and peri-
natal vertically transmitted urogenital infections (UGI). We have evaluated the antimicrobial activities of short-chain (C12) n-al-
kyl QAS against several STI and UGI pathogens as well as against commensal Lactobacillus species. Inhibition of infection of
HeLa cells byNeisseria gonorrhoeae and Chlamydia trachomatis was studied at concentrations that were not toxic to the HeLa
cells. We show that the pathogenic bacteria are muchmore susceptible to QAS toxic effects than the commensal vaginal flora and
that QAS significantly attenuate the infectivity ofN. gonorrhoeae and C. trachomatis without affecting the viability of epithelial
cells of the vaginal mucosa.N-Dodecylpyridinium bromide (C12PB) was found to be the most effective QAS. Our results strongly
suggest that short-chain (C12) n-alkyl pyridinium bromides and structurally similar compounds are promising microbicide can-
didates for topical application in the prophylaxis of STI and perinatal vertical transmission of UGI.
Despite advances inmodernmedical care, sexually transmittedinfections (STI) and perinatal urogenital infections (UGI)
are major global causes of illness, infertility, and death (1). If left
untreated, curable STI are known to facilitate HIV infection and
transmission (2) and are also intimately associated with congeni-
tal and perinatal infections in neonates (3). In recent years, the
significant increase in multidrug-resistant pathogens, together
with the lack of effective vaccines, makes the prevention of STI a
challenge. Currently available options for prevention of STI are
essentially restricted to condoms (4), but limited economic re-
sources and gender inequality may narrow women’s ability to ne-
gotiate consistent condomuse with their sexual partners. Safe and
effective topical microbicides, such as vaginal gels, represent one
of the most promising prevention strategies. Perinatal vertically
transmitted UGI are also canonically prevented by timely screen-
ing and antibiotic treatments of pregnant women, but the en-
forceability of these procedures is very dependent upon the socio-
economic context. A one-time use of topical microbicides may
offer a prophylactic solution for intrapartum transmission of UGI
from the mother to the neonate (5), particularly in those cases in
which canonical antibiotic treatments are either not available or
not adequately carried out. The microbicidal activity of quater-
nary ammonium compounds (QAC)makes these compounds at-
tractive and cheap prophylactic alternatives (6).
All surfactants are toxic to all cells at concentrations that cause
membrane dissolution, but selective toxicity at lower concentra-
tions to bacterial cells, as opposed tomammalian epithelial cells, is
observed only for quaternary ammonium surfactants (QAS), a
subfamily of the QAC (7, 8). We have recently reported detailed
studies on themechanisms of QAS toxicity tomammalian (9) and
bacterial (8) cells at concentrations at which cell membrane dis-
solution does not occur. Our results indicated that while QAS
toxicity to mammalian cells was primarily due to surfactant-in-
ducedmitochondrial dysfunction (9), the toxic action on bacteria
was considerably more complex (8), involving impairment of
bacterial energetics and cell division at low concentrations and
membrane permeabilization and electron transport inhibition
at slightly higher doses. From the perspective of concentration
dependence of QAS toxicity, the differences between mammalian
and bacterial cells is more pronounced for the short-chain QAS,
contrary to what is frequently stated in the literature (10). QAS
having n-alkyl groups with 10 to 12 carbons discriminate better
between the host cells and the pathogens than do their respective
homologues with 14 to 16 carbons (7, 8) and offer a sufficiently
large therapeutic window to merit research on their use as topical
vaginal antiseptics.
Here, we have expanded our studies on (C12) n-alkyl QAS an-
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timicrobial properties and examined their activity against several
STI andUGI pathogens as well as against commensal Lactobacillus
species. Three analogous n-alkyl-QAS families, pyridinium bro-
mide (PB), benzyl-dimethylammonium bromide (BZK), and
trimethylammoniumbromide (TAB), with the same (C12) n-alkyl
chainwere compared. The reasoning that led to the choice of these
analogues has been discussed in previouswork (7–9, 11).We show
that the studied pathogenic bacteria aremuchmore susceptible to
QAS toxic effects than the commensal vaginal bacterial flora and
vaginal mucosa cells. C12PB was found to be the most effective
among the QAS tested. More importantly, besides reducing the
capacity for primary infection (first-round infectivity), QAS also
significantly attenuated the second-generation infectivity ofChla-
mydia trachomatis and reduced the viability of the gonococci that
were capable of infecting HeLa cells.
MATERIALS AND METHODS
Reagents. QAS of the highest commercially available purity, N-dode-
cylpyridinium bromide (C12PB), N-dodecyltrimethylammonium bro-
mide (C12TAB), and N-dodecyl-N-benzyl-N,N-dimethylammonium
bromide (C12BZK), were purchased from Sigma-Aldrich and used as re-
ceived. All mammalian cell culture reagents and Hanks’ balanced salt
solution (HBSS) were purchased fromGibco Life Technologies S.A, agar-
agar was obtained from Merck, Todd-Hewitt broth was from Difco, and
the Trichomonasmedium no. 2, Lactobacilli MRS agar plates, and Lacto-
bacilli MRS broth were from Oxoid. Chocolate agar PolyViteX and Co-
lumbia agar plus 5% sheep blood agar were purchased from bioMérieux.
Anti-Neisseria gonorrhoeae conjugated with fluorescein isothiocyanate
(FITC) (ab20815) and anti-MOMP (major outermembrane protein ofC.
trachomatis strain L2) antibodies were obtained from Abcam, and antitu-
bulin (clone B-5-1-2) was from Sigma-Aldrich. Secondary fluorescent
antibodies were from Molecular Probes Invitrogen Corporation or Jack-
son ImmunoResearch Laboratories. All other chemicals used were from
Sigma-Aldrich.
Microorganism strains, growth conditions, and antimicrobial sus-
ceptibility. A total of 21 microorganisms (listed in Table 1) were exam-
ined. All isolates belong to the stock culture collection of the STI reference
laboratory from the PortugueseNational Institute of Health, unless stated
otherwise. Before each experiment, frozen stocks of all strains were sub-
cultured at least once to check strain viability, and inocula were prepared
accordingly. Briefly, for Trichomonas vaginalis, each frozen stock was first
centrifuged at 3,000 rpm for 5 min at 24°C before being cultured in fresh
sterilemedium at 35°C, and inocula of 1.275 106 cells/ml were prepared
directly from each 48-h subculture. For the fastidious bacteria Neisseria
gonorrhoeae, Streptococcus agalactiae, and Lactobacillus spp., each inocu-
TABLE 1 Bacterial and protozoan strains used in this study
Species and strain ID Type Source of isolation Clinical information
Age
(yr) Gender
Country of
origin or ATCC
ID
Antibiotic(s) to which
organism is resistant
Lactobacillus acidophilus
Scav ATCC 4356
Lactobacillus jensenii
62G ATCC 25258
Streptococcus agalactiae
681 II-2 ST-109 Cerebrospinal fluid Meningitis 12 F Angola Erythromycin
5234 III-2 ST-174 Cerebrospinal fluid Meningitis 12 F Angola
277/10 V Vaginal fluid 46 F Portugal Erythromycin,
clindamycin
354/10 II Vaginal fluid 39 F Portugal Erythromycin,
clindamycin
1078/09 IV ST-28 CC19 Vaginal fluid 46 F Portugal Erythromycin,
clindamycin
1109/08 IV ST-291 CC17 Vaginal-rectal exudate 27 F Portugal
NEM316 III-3 ST-23 Cerebrospinal fluid Meningitis 1 ATCC 12403
2603V/R V ST-110 CC19 ATCC BAA-611
Neisseria gonorrhoeae
PT07-15 ST-878 Synovial fluid Arthritis 40 F Portugal
PT07-54 ST-3618 Pelvic biopsy Pelvic mass 33 F Portugal Ciprofloxacin
PT09-15 ST-2 Conjunctival exudate Conjunctivitis 1 M Portugal
PT09-78 ST-1034 Pharynx exudate Pharyngitis 58 M Portugal
PT10-12 ST-2992 Rectal exudate Proctitis 20 M Portugal
PT12-100 ST-8345 Urethral exudate Urethritis 41 M Portugal Ciprofloxacin
PT13-15 ST-2400 Conjunctival exudate Conjunctivitis 1 F Portugal Ciprofloxacin
PT13-105 ST-10063 Urethral exudate Urethritis 24 M Portugal Ciprofloxacin
Chlamydia trachomatis
LGV II, strain 434 LGV Bubo ATCC VR-902B
Trichomonas vaginalis
162212 Vaginal fluid 32 F Portugal
166391 Vaginal fluid 45 F Portugal
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lum was prepared by making 0.5 McFarland saline–phosphate-buffered
saline (PBS) suspensions (1.5  108 CFU/ml) of isolated colonies se-
lected from 24- to 48-h plates of chocolate agar, 5% sheep-blood agar, or
MRS agar, respectively, incubated at 35 to 36°C in 5% CO2. The MIC for
each QAS assayed was determined by the broth microdilution method
(12, 13), using a 1:20 dilution of the prepared inoculum for all microor-
ganisms, except for T. vaginalis, for which a 1:10 dilution was used. Two-
fold serial dilutions of concentrated stock QAS solutions (0.4 to 1.6 mM)
were prepared in the required medium into 96-well plates. A control
without QAS was also prepared. All cultures were incubated for 18 to 48 h
in an orbital shaker (200 rpm) at 35 to 37°C with 5% CO2. Purity check
and colony or viable cell counts of the inoculum suspensions were also
evaluated in order to ensure that the final inoculum density closely ap-
proximates the intended number. The MIC was determined as the lowest
QAS concentration at which no visible growthwas observed. Optical den-
sities were measured at 600 nm, except for T. vaginalis, for which micro-
scopic observation was performed. These assays were done in triplicate.
Cell culture and MTT assay. HeLa 229 cells (ATCC CCL-2.1) were
seeded in 96-well plates and grown inDulbecco’s modified Eaglemedium
(DMEM) with GlutaMAX, supplemented with 10% fetal bovine serum
(FBS), 100 units/ml of penicillin, and 100g/ml streptomycin, at 37°C in
5%CO2 for 24 h, when they reached confluence. The End1/E6E7 immor-
talized human endocervical epithelial cell line (14)was kindly provided by
Raina Fichorova of the Brigham andWomen’sHospital, HarvardMedical
School (Boston,MA,USA). Cells weremaintained in keratinocyte serum-
free medium supplemented with 50 g/ml bovine pituitary extract, 0.1
ng/ml human transferrin, and CaCl2 to a final concentration of 0.4 mM.
Cells were seeded in 96-well plates and grown until confluence (24 h) at
37°C in 5% CO2. The cells were then incubated with increasing QAS
concentrations for 1 h. Stock solutions of surfactants were prepared in
Opti-MEM cell culture medium, without serum and antibiotics, as mul-
tiples of the respective critical micelle concentration (CMC) (11). At the
end of the incubation, QAS-containing medium was replaced by fresh
complete culture medium without phenol red. Cell viability was assessed
immediately or 24 h after exposure to QAS by the 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (15). The
samples were quantified colorimetrically at 570 nm (background wave-
length correction at 620 nm) on a SpectraMax Plus384 microplate spec-
trophotometer (Molecular Devices Inc.). The background absorbance
(culturemedium plusMTTwithout cells) was subtracted from the absor-
bance of each sample, and data are shown as percentages of control. Dose-
response toxicity curves were fitted using the Hill equation (16), through
computer-assisted curve fitting (SigmaPlot 11.0). From these analyses, it
was possible to calculate the 10% inhibitory concentration (IC10; i.e., the
concentration at which cell viability was 10% of that of the control), IC50,
and IC90 for each data set.
Infection of epithelial cells with N. gonorrhoeae. Gonococcal infec-
tion assays were performed by a standard method (17, 18), with slight
modifications. HeLa cells were grown in glass coverslips or in 48-well
plates until reaching confluence. After that, cells were washed and cell
culture medium was replaced by Opti-MEM serum- and antibiotic-free
culture medium. N. gonorrhoeae PT07-15 cells from a 24-h plate were
resuspended in Opti-MEM to achieve a final multiplicity of infection
(MOI) of 100. Bacteria were allowed to adhere for 1 h at 37°C in a CO2
incubator, in the presence or absence of each of the QAS. Cells were then
washed with PBS, followed by 3 h of incubation with DMEM supple-
TABLE 2MICs and relative antimicrobial efficacy (MIC/CMC)a
Organism and strain ID
C12TAB C12BZK C12PB
MIC (M) MIC/CMC MIC (M) MIC/CMC MIC (M) MIC/CMC
Lactobacillus acidophilus
Scav (ATCC 4356) 50 0.014 25 0.015 50 0.013
Lactobacillus jensenii
62G (ATCC 25258) 100 0.028 100 0.059 100 0.026
Streptococcus agalactiae
2603V/R (V, ST-110, CC19) (ATCC BAA-611) 25 0.007 6.25 0.004 12.5 0.003
NEM316 (III-3, ST-23) (ATCC 12403) 50 0.014 6.25 0.004 25 0.006
277/10 (V) 12.5 0.003 3.13 0.002 6.25 0.002
354/10 (II) 25 0.007 6.25 0.004 12.5 0.003
1078/09 (IV, ST-28, CC19) 25 0.007 6.25 0.004 12.5 0.003
1109/08 (IV, ST-291, CC17) 25 0.007 3.13 0.002 6.25 0.002
681/04 (II-2, ST-109) (Angola) 25 0.007 3.13 0.002 12.5 0.003
5234/05 (III-2, ST-174) (Angola) 25 0.007 3.13 0.002 6.25 0.002
Neisseria gonorrhoeae
PT07-15 25 0.007 6.25 0.004 12.5 0.003
PT07-54 25 0.007 12.5 0.007 12.5 0.003
PT09-15 25 0.007 6.25 0.004 12.5 0.003
PT09-78 25 0.007 6.25 0.004 12.5 0.003
PT10-12 50 0.014 25 0.015 25 0.006
PT12-100 25 0.007 6.25 0.004 6.25 0.002
PT13-15 25 0.007 12.5 0.007 12.5 0.003
PT13-105 25 0.007 12.5 0.007 12.5 0.003
Trichomonas vaginalis
162212 400 0.114 200 0.118 200 0.051
166391 400 0.114 200 0.118 200 0.051
a MICs were determined according to the established procedures recommended for each strain. The critical micelle concentration (CMC) values for the QAS used have been
previously reported by us (11) and are as follows: C12TAB, 3.5 10
3 M; C12BK, 1.7 10
3 M; C12PB, 3.9 10
3 M.
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mentedwith 10%FBS at 37°C and 5%CO2, to allow the internalization of
the attached bacteria. For fluorescence cell imaging assays, cells were fixed
with ice-cold methanol for 10 min and immunolabeled with an anti-N.
gonorrhoeae FITC antibody. Images were taken in a Carl Zeiss laser scan-
ning confocal microscope LSM 510. The percentage of infected cells and
the number of infecting particles per infected cell were determined and
compared with the values for untreated controls. To assay for bacterial
invasion and evaluate the viability of the gonococci that were capable of
infecting host cells, cell monolayers were washed with PBS, followed by
the addition of 100 l of PBS supplemented with 0.5 mM EDTA to each
well. Cells were scraped off and collected, vortexed vigorously for 1 min,
serially diluted, spread on chocolate agar plates, and incubated for 48 h at
37°C in a CO2 incubator. CFU were counted to determine the number of
viable bacteria. Data are presented as CFU/105 epithelial cells.
Infection of epithelial cells by C. trachomatis. C. trachomatis L2/
434/Bu (ATCC VR-902B) was propagated in HeLa cells using standard
techniques (19). To test the effect of the QAS on C. trachomatis in vitro
infection, HeLa cells seeded the day before on 24-well plates were equili-
brated in HBSS and incubated at 37°C with C. trachomatis for 1 h at an
MOI of 5, in the presence or absence of each of the QAS. The cells were
then washed with culture medium containing 10 g/ml gentamicin, but
without penicillin or streptomycin, and incubated in this medium at
37°C. At 24 h postinfection, cells that had been seeded on glass coverslips
were fixed with methanol for 5 min at 20°C and processed for immu-
nofluorescence microscopy using monoclonal antibodies against the ma-
jor outer membrane protein (MOMP), to enable the estimation of the
number of infected cells and the volume of the vacuoles enclosing C.
trachomatis. At 44 h postinfection, the number of infectious C. trachoma-
tis progeny present was estimated after osmotic lysis of the infected cells
withH2O, followed by serial dilutions of the lysates in sucrose-phosphate-
glutamate buffer that were used to infect HeLa cells seeded the day before
on glass coverslips in 24-well plates. After 24 h of infection, the cells were
fixed in methanol for 5 min at 20°C and immunolabeled as described
above. Inclusions in 20 to 25 fields of viewwere counted in the appropriate
dilutions (10 to 50 inclusions per field of view) using a Leica DMRA2
microscope with a 40 objective (numerical aperture [NA], 0.75). Inclu-
sions per field of view were transformed into inclusion-forming units
(IFU) per milliliter (19).
Morphometric analysis of chlamydial inclusions was carried out in
confocal optical sections of cells labeled with an anti-MOMP C. tracho-
matis antibody. Image acquisitions were made in a confocal microscope
with an EC-PlanNeofluor 40 oil immersion objective (NA, 1.30) using
the Carl Zeiss laser scanning system LSM 510 software. Surface rendering
was carried out in 5- to 12-m z-stack images composed of 0.7-m opti-
cal slices using Imaris (Bitplane AG). The volume of C. trachomatis inclu-
sions was calculated from this volumetric reconstruction.
FIG 1 Dose-dependent toxicity of QAS to nonpolarized epithelial cells. The effect of C12PB on the viability of endocervical epithelial cells (End1) (A) and of
cervical adenocarcinoma cells (HeLa) (B) was assessed by the MTT assay immediately or 24 h after the cells had been incubated with increasing C12PB
concentrations for 1 h. The C12PB concentration is plotted on a logarithmic scale. Cell viability is expressed as a percentage of the viability of control cells. Data
are presented as means standard deviations (SD) from at least 3 independent experiments, each done in triplicate. The Hill equation was fitted (lines) to the
data. TheCMCofC12PB surfactant is represented by the black dashed line. (C)Tenpercent inhibitory concentration (IC10), 50% inhibitory concentration (IC50),
and 90% inhibitory concentration (IC90), i.e., surfactant concentrations at which cell viability was, respectively, 10%, 50%, and 90%of that of the control for each
time point, were calculated from the theoretical curves adjusted to the dose-response toxicity plots.
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FIG 2 Effect of QAS onN. gonorrhoeae infectivity (concentrations are expressed as multiples of the QAS CMC. (A) Representative maximum fluorescence intensity
projection images obtained by confocal microscopy of HeLa cells infected withN. gonorrhoeae (MOI, 100) for 1 h. C12PB was added at the indicated concentrations
during the infection. N. gonorrhoeae cells were visualized with an anti-Neisseria antibody (green), and the host cell cytoskeleton was visualized with an anti--actin
antibody (red). HeLa cell nuclei were stainedwithHoechst (blue). (B) The percentage of infected cells was determined from the immunofluorescence images, and data
Antimicrobial Activity of QAS
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RESULTS
Antimicrobial activity of short-chain n-alkyl QAS. In order to
evaluate the antimicrobial activity of QAS against bacteria in-
volved in STI and UGI, we determined the MICs of C12PB,
C12BZK, and C12TAB for several Streptococcus agalactiae (Gram-
positive) and N. gonorrhoeae (Gram-negative) strains. The MICs
for these compounds were also determined for somemicroorgan-
isms of the commensal vaginal flora. In previous work (7, 8, 11),
we have argued that the effective biocidal concentrations of QAS
should be compared after normalization relative to their respec-
tive CMC. In what follows, we shall, therefore, compare the effi-
cacy of differentQASusing theCMC-normalizedMIC (MIC/CMC)
values. The rationale for reporting effective QAS concentrations as
CMC-normalized values is explained inmore detail in the supple-
mental text. CMC values for the QAS used have been previously
reported by us (11). Using this definition, the relative antibacterial
efficacy was C12PB 	 C12BZK 	 C12TAB (Table 2). While the
toxicity pattern was similar to that previously described for Esch-
erichia coli (8), QAS were more effective against the pathogenic
bacteria tested, regardless of being Gram-positive or Gram-nega-
tive. For the majority of the analyzed strains, the PB analogue was
at least two times more effective in inhibiting bacterial growth
than theBZKandTABanalogues. In contrast, the tested commen-
sal Lactobacillus spp. were more resistant to QAS effects and no
correlation between the antibacterial activity and QAS polar head
structure was found (MIC/CMC ratios were the same or within a
range of 1 dilution). The biocidal activity of QAS against the pro-
tozoan STI/UGI parasite Trichomonas vaginalis was also exam-
ined. In this case, the inhibitory effectiveness rank of the QAS
examined was C12PB	 C12BZK
 C12TAB. The MIC/CMC val-
ues obtained, however, were two to four times higher for T. vagi-
nalis than for the most resistant bacterium, Lactobacillus jensenii,
suggesting that QAS would be less useful in the prevention of
protozoan STI/UGI than of bacterial STI/UGI.
Toxicity of short-chain n-alkyl QAS to vaginal epithelial
cells. As infections with C. trachomatis andN. gonorrhoeae are the
most common bacterial STI and the most prevalent coinfections
with HIV (1, 2), we studied the potential of QAS to inhibit these
infections using an in vitromodel. The primary target for bacterial
and viral STI in women is the nonkeratinized squamous epithe-
lium of the vagina and ectocervix, as well as the single-layer co-
lumnar epithelium of the endocervix. Thus, the End1 immortal-
ized epithelial cell line from normal human endocervical tissue
andHeLa epithelial cells originating from an adenosquamous car-
cinoma of the cervix were used as models of female lower genital
tract epithelial cells. It has been shown that both cell lines support
chlamydial growth (20, 21) as well as the attachment and intracel-
lular uptake of piliated N. gonorrhoeae strains (17, 18).
In in vitro experiments that study the invasion of human host
cells in culture by a pathogen, the concentration of the antiseptic
agent used (in our case, QAS) must always be subtoxic to the host
cells used, in our case End1 and HeLa cells. It was therefore im-
portant to determine the toxicity curves of QAS for End1 and
HeLa cell cultures. This was done by evaluating the effects of QAS
on the viability of End1 and HeLa cell lines using the MTT assay
immediately or 24 h after exposure to increasing surfactant con-
centrations for 1 h (Fig. 1A to C). Consistent with our previous
results (9, 11), exposure to QAS resulted in a persistent postexpo-
sure toxicity as can be seen by the low inhibitory concentrations 24
h postexposure compared to those observed immediately after the
end of incubation. TheQAS toxicity ranking for both cell lines was
C12PB 
 C12BZK 	 C12TAB. Despite the fact that, contrary to
HeLa cells, End1 cells can be fully polarized in vitro, resembling
the morphological characteristics of epithelial cells of the vaginal
mucosa (14), maturity of tight junctions is achieved only after 8 to
10 days in culture (22). Consequently, under our experimental
conditions, End1 cells lack mature nonleaky tight junctions, jus-
tifying the similar IC50s determined for End1 andHeLa cells. Since
no significant differences in QAS susceptibility of these two cell
lines were observed, further experiments were performed in HeLa
cells as this cell line is easier to grow and maintain in culture. In
previous work (8), we showed that the therapeutic indices (deter-
mined using a fully polarized columnar epithelial cell line) after 60
min of exposure to C12PB were 10 for a multidrug-resistant
strain of E. coli and	20 for the most resistant strain of N. gonor-
rhoeae tested. Nonpolarized epithelial cells aremore susceptible to
QAS toxicity than fully polarized columnar epithelial cell lines, in
which the tight junctions are well formed (11), so it is expected
that the therapeutic indices are somewhat lower in the case of the
nonpolarized cells. Nevertheless, they are useful practical models
for infectivity. Therefore, in what follows, HeLa cells were used
and the QAS concentrations were always lower than those that
were toxic to HeLa cells.
Effect ofQASonN. gonorrhoeae infectivity. Invasion ofHeLa
cells byN. gonorrhoeae and its attenuation by C12PB are shown in
Fig. 2. Although C12PB apparently had a very small effect on the
percentage of infected cells at the concentrations tested (Fig. 2A
and B), a significant reduction in gonococcal invasion was de-
tected, as indicated by the lower numbers of internalized bacteria
(Fig. 2A and C). In the absence of C12PB (control) the average
number of infecting particles per infected cell was 12.6, whereas in
cells treatedwithC12PB it was only 4.3 at a concentration of CMC/
150 (P 0.001). In order to evaluate the viability of the gonococci
that were capable of infecting host cells, N. gonorrhoeae-infected
HeLa cells were lysed 3 h postinfection and lysates were diluted
and spread onto agar plates to estimate the number of recovered
CFU per epithelial cell. As shown in Fig. 2D, a C12PB concentra-
tion as low as CMC/500 reduced the number of CFU recovered by
a factor of 1,000 and at CMC/150 by 10,000. The results obtained
for C12BZK were similar to those of C12PB (Fig. 2E to G), whereas
C12TAB was less efficient in attenuating gonococcal infection,
are presented as means SD from 3 independent experiments. For each sample, at least 200 cells were analyzed. (C) Effects of C12PB on the number of infecting
particles per infected cell (box-and-whisker plot). For each sample, at least 30 infected cells were analyzed. Boxes indicate the median and the 25th to 75th
percentiles for 3 independent experiments, while the whiskers represent the lowest and highest values (data range). Outliers are represented by the black circles.
Kruskal-Wallis test (Dunn’s posttest): ***,P 0.001 (significantly different from control). (D)CFU recovered 3 h postinfection from105HeLa cells. Recoverable
CFU/105 epithelial cell (x axis) values are logarithmically transformed. Each independent experiment is represented by a closed triangle. Lines indicate themeans
for 3 independent experiments.One-way analysis of variance (ANOVA) test (Bonferroni’s posttest): **,P 0.01; ***,P 0.001 (both significantly different from
control). (E to J) Effects of C12BZK (E to G) and C12TAB (H to J) on N. gonorrhoeae infectivity. Details are as indicated for C12PB.
Inácio et al.
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FIG 3 Effect of QAS on C. trachomatis infectivity (concentrations are expressed as multiples of the QAS CMC. (A) Representative fluorescence confocal images
of HeLa cells infected byC. trachomatis (MOI, 5) for 24 h. C12PB was added at the indicated concentrations for 1 h during the initial inoculation of the cells with
C. trachomatis. After this initial incubation, C12PB was washed out and the infection proceeded for the indicated times. Cells are costained with anti-MOMP
(major outer membrane protein) of C. trachomatis (green) and -tubulin (red) antibodies and 4=,6-diamidino-2-phenylindole (DAPI) (blue). (B) Immunoflu-
orescence images were used to estimate the number of infected cells (i.e., cells showing inclusions) 24 h postinfection. For each sample, at least 450 cells were
Antimicrobial Activity of QAS
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higher concentrations being necessary to achieve comparable re-
sults (Fig. 2H to J).
Effect of QAS on C. trachomatis infectivity. C. trachomatis
replicates exclusively within host cells in a membrane-bound vac-
uole, the inclusion, undergoing a developmental cycle whereby it
alternates between the infectious, but nonreplicative, elementary
bodies (EBs) and the noninfectious, but replicative, reticulate
bodies (23). To understand if QAS interfere with the Chlamydia
infectious cycle, HeLa cells were inoculated for 1 h with C. tracho-
matis strain L2/434, in the absence or presence of QAS concentra-
tions that were previously determined to be subtoxic for the HeLa
cells. The strain of C. trachomatis that we used is widely used in
studies of Chlamydia-host cell interactions. Although infections
caused by this serovar are less common than those caused by other
strains and the pathogenicity profiles of the different serovars are
distinct, they all share 98% identity at the nucleotide level. Hence,
there is no reason to expect that the surfactants would behave
differently toward distinct C. trachomatis serovars in a tissue cul-
ture model of infection.
Analysis of the number of infected cells 24 h postinfection
showed that C12PB inhibited the infection of HeLa cells by C.
trachomatis in a dose-dependent manner, as seen by a decrease in
the percentage of cells bearing visible inclusions, from 56.9% 
5.9% under control conditions to 27.6%  14.9% at CMC/150
(Fig. 3A and B). Additionally, cultures that had been incubated
withC12PB resulted in inclusionswith amuch smaller size (Fig. 3A
and C), strongly suggesting that C12PB inhibits the intracellular
growth of C. trachomatis. In fact, at CMC/150, inclusions are dif-
ficult to find due to their abnormally small size.
The effects of C12PB on the formation of C. trachomatis infec-
tious progeny (EBs) were also investigated. Cells infected in the
absence or presence of QAS were lysed 44 h postinfection, and
lysates were used to infect freshly seeded cells. Twenty-four hours
after secondary infection, quantification of recovered IFUs was
performed. As can be seen in Fig. 3D, C12PB significantly de-
creased the formation ofC. trachomatis infectious progeny, show-
ing a substantial reduction in the recovered IFUs (in theworst case
from six independent experiments, at least by a factor of 10 at
CMC/500, while the mean value of the recovered IFUs showed a
reduction of 7 orders of magnitude), a much stronger effect than
that observed for the primary infection. At higher concentrations
(i.e., CMC/300 and CMC/150), secondary infection was virtually
abolished (for both concentrations in five of six independent ex-
periments, no IFUs were recovered). In contrast, while the results
obtained for C12BZK regarding the percentage of infected cells
were similar to those of C12PB, C12BZKwas less effective in inhib-
iting the formation of C. trachomatis infectious progeny in the
same concentration range (Fig. 3E to G). C12TAB was also less
effective in attenuating chlamydial infection, similar to what was
observed forN. gonorrhoeae infectivity, and higher concentrations
were necessary to achieve similar results (Fig. 3H to J). As dis-
cussed in some detail by us earlier (8), we believe the differences
between the PB and the TAB/BZK derivatives to be a consequence
of the delocalized positive charge in the polar head group of C12PB
that facilitates its translocation across the membranes of the host
cells, exposing the invading infectious agents for an effectively
longer time to this QAS.
DISCUSSION
The urgent need for woman-controlled, safe, and effective topical
microbicides for the prevention of STI makes QAS-containing
formulations an interesting option, since QAS have a well-known
antimicrobial activity, combined with a low price and excellent
chemical stability. Topical microbicides could also be a prophy-
lactic solution for perinatal vertically transmitted UGI. Mother-
to-child transmission of UGI can be prevented by screening
pregnant women for these infections and providing antibiotic
treatment to them before term or during childbirth. Yet, one
major problemwith these infections is their discontinuous nature:
themother can be infected at the time recommended for screening
and no longer when going into labor or vice versa. In the first
scenario, the canonical treatment and consequent protection will
be provided, whereas in the second it will not. Additionally, when
the canonical preterm protocols for pregnant women are not rig-
orously adhered to, a last-recourse prophylactic antiseptic treat-
ment at term may be recommendable in order to avoid, or atten-
uate, the probability of vertical transmission. Potentially, the
routine use of a microbicide gel immediately prior to term could
dispense screening and unnecessary use of antibiotics while elim-
inating, or at least significantly attenuating, the risk of infection,
but this will require further work in vivo. This aspect is of partic-
ular relevance in places where the standard procedures used in
“developed” countries are either not available or not rigidly ad-
hered to.
The results reported in the present paper show that the patho-
genic bacteria analyzed were muchmore susceptible to QAS toxic
effects than commensal Lactobacillus species. This difference in
QAS susceptibility is of particular importance since lactobacilli are
women’s predominant members of the commensal vaginal flora
(24), playing a central role in themaintenance of a low vaginal pH
and contributing to avoid colonization of the urogenital tract by
pathogenic bacteria (25, 26). An acidic vaginal pH has also been
correlated with a decrease in HIV infection (27, 28). Recent stud-
ies employing cultivation-independent molecular approaches
showed that the vaginal microbiome (VMB) is much more com-
plex than previously appreciated and that conventional culture
analyzed. Data are presented as means SD for 6 independent experiments. One-way ANOVA test (Bonferroni’s posttest): **, P 0.01; ***, P 0.001 (both
significantly different from control). (C) Images obtained by combining a z series of 12 to 20 optical slices taken at 0.7-m intervals were used to quantify the
volume of inclusions 24 h postinfection (box-and-whisker plot). For each sample, at least 30 inclusions were analyzed. Boxes indicate medians and 25th to 75th
percentiles for 4 independent experiments, while the whiskers represent the lowest and highest values (data range). Outliers are indicated by the black circles.
Kruskal-Wallis test (Dunn’s posttest): ***, P 0.001, significantly different from control. (D) Effect of C12PB treatment on the formation of infectious progeny
of C. trachomatis. HeLa cells were infected by C. trachomatis L2/434 in the presence of the indicated concentrations of C12PB, as described for panel A. After 44
h of infection, the cells were harvested, and the lysate was used to reinfect HeLa cells for 24 h. The number of inclusion-forming units (IFU) permilliliter of lysate
was then determined after immunofluorescence microscopy of the infected cells, as detailed in Materials and Methods. IFU per milliliter (x axis) values are
logarithmically transformed. Each independent experiment is represented by a closed triangle. Lines indicate themeans for 6 independent experiments. One-way
ANOVA test (Bonferroni’s posttest): ***,P 0.001, significantly different from control. (E to J) Effects of C12BZK (E toG) andC12TAB (H to J) onC. trachomatis
infectivity. Details are as indicated for C12PB.
Inácio et al.
3330 aac.asm.org June 2016 Volume 60 Number 6Antimicrobial Agents and Chemotherapy
techniques are limited, allowing the detection of only a small frac-
tion of themicroorganisms in the vaginal flora (29, 30). Therefore,
detailed studies on the effects of QAS on the VMB, employing
genetically controlled ex vivomodels in combination with cultiva-
tion-independent methods (31, 32), should be performed in the
future. This kind of approach will allow a more detailed anal-
ysis of the effects of QAS not only on healthy VMB but also on
dysbiotic VMB collected from patients with bacterial vaginosis
(32), the most common cause of vaginal infection in women of
childbearing age, a main factor of increased susceptibility to
infection by HIV and other STI (29). QAS, being neutral salts,
will not alter vaginal pH directly, but indirect effects through
alterations of the VMB cannot be excluded at this stage. Yet
other important considerations are the effects of long-term
exposure to QAS, their potential to act as inflammatory agents,
and the likelihood of bacteria developing resistance (or core-
sistance to other antibiotics). While these aspects need to be
assessed in future studies, the results reported in this paper
suggest that short-chain QAS should be regarded as potentially
valuable topical microbicides.
Of the QAS analyzed, C12PB was found to be the most effec-
tive, which is in agreement with our previous results for E. coli
(8). In addition, QAS were shown to attenuate C. trachomatis
andN. gonorrhoeae infections at very low concentrations that do
not affect the viability of nonpolarized host epithelial cells in
vitro. More importantly, the decrease in pathogen infectivity is
even greater when the secondary infectivity of these pathogens
is considered. This suggests not only that a one-time applica-
tion could reduce the risk of vertical transmission of infection
but also that repeated topical application of C12PB may have a
curative potential for established infections by both N. gonor-
rhoeae and C. trachomatis without recourse to systemic antibi-
otic treatment.
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